// App-Quantinova.ai

395 : METHYLENE BLUE MMX® INCREASES ADENOMA DETECTION RATE IN SCREENING AND SURVEILLANCE COLONOSCOPY- A MULTI-CENTRE, MULTINATIONAL, PLACEBO CONTROLLED, RANDOMISED, DOUBLE-BLIND AT RANDOMISATION, PARALLEL-GROUP, PHASE III STUDY

Researchers

Presenter

  • Alessandro Repici

Principal Investigators

  • James East

  • Prateek Sharma

  • Raf Bisschops

  • Francisco C. Ramirez

  • David H. Bruining

  • Michele A. Young

  • David Gatof

  • Marcia I. Canto

  • Norman E. Marcon

  • Renato Cannizzaro

  • Ralf Kiesslich

  • Matt Rutter

  • Evelien Dekker

  • Peter D. Siersema

  • Manon Spaander

  • Limas Kupcinskas

  • Franco Radaelli

  • Pradeep Bhandari

  • Michael Vieth

  • Cesare Hassan

Medical Centers

  • Digestive Endoscopy Unit, Istituto Clinico Humanitas, Milan, Italy

  • Mayo Clinic, Jacksonville, FL

  • Translational Gastroenterology Unit, University of Oxford, Oxford, United Kingdom

  • Kansas City Veterans Affairs Hospital, Kansas City, MO

  • University Hospitals Leuven and KU Leuven, Leuven, Belgium

  • Mayo Clinic, Scottsdale, AZ

  • Mayo Clinic, Rochester, MN

  • VA Medical Center, Phoenix, AZ

  • Clinical Research of the Rockies, Lafayette, CO

  • The Johns Hopkins Hospital, Baltimore, MD

  • St. Michael's Hosp, Toronto, ON, Canada

  • Centro di Riferimento Oncologico di Aviano, Aviano, Italy

  • Dr. Horst Schmidt Klinik, Wiesbaden, Germany

  • University Hospital North Tees, Stockton-Cleveland, United Kingdom

  • Academic Medical Center, Amsterdam, Netherlands

  • University Medical Center Utrecht, Utrecht, Netherlands

  • Erasmus University Medical Center, Rotterdam, Netherlands

  • University of Medicine, Kaunas, Lithuania

  • Valduce Hospital, Como, Italy

  • Queen Alexandra Hospital, Portsmouth, United Kingdom

  • Institute of Pathology, Klinikum Bayreuth GmbH, Bayreuth, Germany

  • Nuovo Regina Margherita hospital, Rome, Italy

Locations

  • Italy

  • United States

  • United Kingdom

  • Belgium

  • Canada

  • Germany

  • Netherlands

  • Lithuania

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Aldo-Keto Reductase Family 1 Member B

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multinational

  • Multicenteric

  • Controlled

  • Parallel Group

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved